Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Ag
June 04 2007 - 9:00AM
PR Newswire (US)
Data from the Randomized, Double-Blind, Placebo-Controlled Phase II
Trial Presented at ASCO HOUSTON, June 4 /PRNewswire/ -- Agennix
Incorporated today announced results from a fourth positive Phase
II trial with its lead molecule talactoferrin alfa, an
immunomodulatory protein with a novel mechanism of action. This
trial, which compared oral talactoferrin monotherapy to placebo in
patients with refractory non-small cell lung cancer (NSCLC), met
its primary endpoint of a statistically significant improvement in
overall survival. Secondary efficacy endpoints also showed
improvement consistent with the primary endpoint results. Oral
talactoferrin was well tolerated in this patient population with
fewer adverse events observed in the talactoferrin arm. These data
were presented Saturday, June 2, at the 2007 American Society of
Clinical Oncology (ASCO) Annual Meeting in Chicago. Oral
talactoferrin significantly improved overall survival in this
study. In the 100-patient intent-to-treat (ITT) population, median
overall survival was 62% higher in the talactoferrin group than in
the placebo group - 6.0 months versus 3.7 months, respectively
(hazard ratio=0.69; p=0.0476). In the 81-patient
prospectively-defined evaluable population, the median overall
survival was 73% higher in the talactoferrin group than in the
placebo group - 7.6 months versus 4.4 months, respectively (hazard
ratio=0.60; p=0.0213). The six-month survival rate in the ITT
population was also significantly better in the talactoferrin group
(49%) than the placebo group (28%), p=0.0276. In addition, overall
survival improvement trends were consistent across subsets of
patients grouped by prognostic factors, including disease stage,
performance status, and line of therapy. In addition to improving
overall survival, oral talactoferrin was well tolerated by
refractory NSCLC patients. Adverse events (AEs) were generally
mild, and no drug-related serious AEs were reported. In addition,
there were 28% fewer AEs and 51% fewer Grade 3/4/5 AEs in the
talactoferrin group relative to the placebo group (p=0.0015 and
p=0.0005, respectively). This was the second successful
placebo-controlled trial with oral talactoferrin in NSCLC. The
first was in combination with first-line chemotherapy. Preparations
for Phase III trials with talactoferrin are underway in both NSCLC
indications: (i) first-line in combination with chemotherapy, and
(ii) single-agent treatment of patients with refractory disease.
About the Study In this Phase II single-agent study, 100 patients
with stage IIIB/IV NSCLC, whose cancer had progressed after first-
or second-line chemotherapy, were enrolled at 10 leading oncology
centers in India and randomized to receive standard supportive care
plus either placebo (n=53) or talactoferrin 1.5 g orally twice a
day (n=47). Patients did not receive any other anti- cancer therapy
while on the trial. Treatment was administered in 14-week cycles
(12 weeks on, two weeks off) for up to three cycles or until
disease progression. The primary endpoint was overall survival. All
100 patients were included in the ITT population. The 81 patients
who had at least one CT scan after initiating treatment were
prospectively defined as the evaluable population. About
Talactoferrin Alfa Talactoferrin alfa is a unique recombinant form
of human lactoferrin, an immunomodulatory protein. Talactoferrin
acts by binding to specific receptors found on target cells and
inducing the production of key immunomodulatory cytokines and
chemokines. Orally administered talactoferrin binds to enterocytes
lining the upper gastrointestinal tract, initiating an
immunostimulatory cascade in the gut associated lymphoid tissue.
This results in the activation of both innate and adaptive
immunity, including recruitment and activation of dendritic cells,
NK-T cells and CD8+ lymphocytes. This is followed by systemic
immunostimulation, the activation of tumor-draining lymph nodes,
and infiltration of distant tumors by immune cells, which results
in killing of the cancer cells. Topically administered
talactoferrin binds to keratinocytes and fibroblasts and increases
the local production of cytokines and chemokines critical to wound
healing. Both oral and topical formulations of talactoferrin appear
to be well tolerated. Over 600 patients have been dosed with
talactoferrin, including patients who had exposure to talactoferrin
lasting over two years, without any drug-related serious AEs. About
NSCLC In the United States, lung cancer is the second most frequent
cancer in both men (next to prostate cancer) and women (next to
breast cancer). It remains the major cause of cancer death, killing
more people than breast cancer, prostate cancer and colorectal
cancer combined, and accounting for almost 30% of all
cancer-related deaths. NSCLC accounts for approximately 80% of all
new lung cancer cases, with approximately 150,000 patients in the
United States and 300,000 patients in Europe diagnosed each year.
Most patients diagnosed with NSCLC have late- stage disease (Stage
IIIB or IV), which is not surgically resectable. The current U.S.
standard of care for these patients is systemic chemotherapy. Even
with the available therapy, the five-year survival rate for these
patients is less than 3%. About Agennix Agennix is a private
biotechnology company developing a first-in-class molecule for the
treatment of cancer and for wound healing. This molecule,
talactoferrin, is an immunomodulatory recombinant protein with a
novel mechanism of action. The Company is developing an oral liquid
formulation of talactoferrin for cancer indications, and a topical
gel formulation for the treatment of diabetic foot ulcers. Agennix
has 95 issued patents and 47 pending patents broadly protecting
talactoferrin composition of matter, use, and manufacturing
methods. More information about Agennix is available on the
Company's web site at http://www.agennix.com/. DATASOURCE: Agennix
Incorporated CONTACT: Daniel Budwick of BMC Communications Group,
+1-212-477-9007, ext. 14 Web site: http://www.agennix.com/
Copyright